Watch More Highlights
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the dual inhibition of Bruton’s tyrosine kinase and BCL2; with the combination of venetoclax and ibrutinib, this drug combination may have broad therapeutic indications (Abstract 214).